Skip to main content

NCBiotech News

  • Four Triangle pharmaceutical companies have shared in good news in recent days.
  • Bioscience briefs with names making news
  • Durham-based Bioventus, a global orthobiologics company with growing sales revenues, has filed for a $150 million initial public offering (IPO) of stock.
  • The NCBiotech Library will be undergoing a renovation from Friday, July 1 through Tuesday, July 12. If you need to use our market reports or databases, library services will be available by appointment.
  • Mayne Pharma Group, an Australian drug manufacturer with a growing production plant in Greenville, has agreed to acquire a portfolio of generic drugs from Teva Pharmaceutical Industries and Allergan for $652 million.
  • Veristat, a full-service clinical research organization (CRO) based in Southborough, Mass., says it will open an office in the Research Triangle area this fall.
  • Growing demand for natural products by health-conscious consumers has prompted Gaia Herbs to begin a nearly $5 million expansion of its production facilities in Brevard.
  • If your early-stage life science company needs some funding help, you still have a few days to apply for a chance to pitch your company story to investors and colleagues at the 2016 annual Southeast BIO Investor & Partnering Forum.
  • As part of the celebration of the opening of SoBran's Greensboro animal research facility, the company and NCBiotech are co-sponsoring the Innovation for Impact Prize contest for researchers at North Carolina academic institutions and emerging companies – those with fewer than 50 employees and annual revenue under $10 million.
  • Traumatic brain injury has gained national prominence as star athletes have publicly acknowledged their struggles, and now the medical community is sounding the alarm about the prevalence of TBI among soldiers, who face comparable risks as they engage in rigorous training, athletics and combat.
  • More than 125 participated in a day-long symposium at NCBiotech, exploring the bioterrorism challenges our defense and military agencies are charged with assessing and solving, and some of North Carolina's capabilities for helping to deal with the issues.
  • BioFluidica, a Chapel Hill company developing a product using liquid biopsies for cancer detection. has completed a $2 million Series A funding round.
  • CivaTech Oncology, a Research Triangle Park company developing cancer therapy devices with funding help from the North Carolina Biotechnology Center, is featured in an abstract that will get a “Best in Show” award at an upcoming scientific meeting.
  • North Carolina’s life science jobs continue to grow at more than triple the national average, pushing the total num
  • Seventy-one companies headquartered in 20 countries now have a presence in North Carolina, employing more than 17,000 people in the state, where they have made capital investments totaling well over $2.5 billion in the past five years alone.
  • Carver Nichols, a senior honor student at Brevard High School, was a finalist in the BioGENEius Challenge, an international science fair in which North Carolina's lone 2016 finalist competed against 14 others from the United States, Canada and Germany.
  • Wilmington physician Alan Brown, an impassioned inventor in his off hours, has transformed two of his ideas into award-winning product innovations – a self-illuminating speculum and a corneal marking system – designed to make eye surgeries more efficient and accurate, improving patient outcomes.
  • A group headlined by blazingly successful life science rainmaker Steve Butts, MBA, is hanging out a shingle in Morrisville, this time with $49 million in early funding support. They’re calling it Arrivo BioVentures.
  • The uniquely futuristic billion-dollar cell culture Seqirus vaccine factory in Holly Springs has hit another milestone, with U.S. Food and Drug Administration marketing approval for the FLUCELVAX QUADRIVALENT flu vaccine made there.
  • Panacea BioMatx, a personalized nutrition startup company in Morrisville, has signed a license agreement with an Australian health food provider that will also invest up to $1 million in Panacea, while existing North Carolina investors in Panacea have also agreed to match the investment on similar terms.


Subscribe to News & Events